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ABSTRACT
Objectives: The objective of this study was to assess the prescribing pattern, most common indication, and adverse effects associated with angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with cardiovascular diseases, and to identify the risk 
factors associated with cardiovascular diseases in a tertiary care hospital.
Methods: A prospective observational study was carried out for a period of 6 months from October 2016 to March 2017 in both inpatients and 
outpatients of the cardiology department. Patients received either ACEIs or ARBs were enrolled in the study. The relevant details of the patients were 
collected from the patient case note and treatment chart and data analyzed.
Results: Of 100 patients, 23.0% were female and 77.0% were male. Among them, majority of patients were in the age group of 41–60 years. Diabetes 
mellitus (39%), smoking (20%), and alcohol (14%) were the common risk factors. The most common indications of ACEIs were found to be ischemic 
heart diseases (IHDs) (17%) followed by hypertension (HTN)/IHD (12%), and IHD/heart failure (12%). Main indications of ARBs were found in HTN/
IHD (16%). Utilization of ACEIs (70%) was found to be higher when compared with ARBs (30%). Ramipril (69%) and telmisartan (18%) were the 
most commonly used ACEIs and ARBs, respectively. While analyzing the adverse effects of ACEIs and ARBs, about 5.71% of patients were identified 
with ramipril induced dry cough.
Conclusions: The complications of cardiovascular diseases can be reduced by knowing the incidence of risk factors and alternative therapy can be 
initiated by assessing the incidence of adverse drug reactions related to ACEIs and ARBs
Keywords: Angiotensin-converting enzyme inhibitors, Adverse drug reactions, Angiotensin receptor blockers, Cardiovascular diseases, Drug 
utilization, Risk factors.
INTRODUCTION
Cardiovascular disease is a general category of disease that affects 
the heart and the circulatory system [1]. Cardiovascular diseases are 
leading cause of morbidity and mortality in India [2]. According to the 
study conducted by the World Health Organization (WHO) in 2002, 
cardiovascular diseases will be the largest cause of death and affliction by 
2020 in India [3]. Recent trends indicate that the disease has escalated to 
younger age group also, and it is present in both male and female in urban 
and rural population [4]. In the United Kingdom, about one-third of men 
and one quarter of women are dying due to ischemic heart disease (IHD). 
When compared with Eastern Europe and Asia, the incidence of IHD has 
been reduced in the developed countries from the last 20 to 30 years [5].
The various risk factors for cardiovascular diseases include diabetes 
mellitus (DM), smoking, family history, obesity, alcohol, and age. It is 
necessary to control all these risk factors which may otherwise lead to 
various cardiovascular complications such as IHD, stroke, and chronic 
renal failure [6].
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin 
receptor blockers (ARBs) are among the common therapeutic options 
in the treatment of various cardiovascular diseases such as heart failure 
(HF), hypertension (HTN), stroke, mitral valve regurgitation (MR), 
aortic regurgitation (AR), myocardial infarction, and IHDs [7,8].
The WHO defines drug utilization as “the marketing, distribution, 
prescription, and use of drugs in society, with special emphasis on 
the resulting medical, social, and economic consequences” [9]. Drug 
utilization studies are an important tool to examine the use of drug in 
a society [10].
The WHO defines adverse drug reaction (ADR) as “any response to a 
drug which is noxious (or) unintended, and which occurs at doses 
normally used in man for prophylaxis, diagnosis, or therapy of disease 
or the modification of physiological function” [11]. These ADRs can 
be minimized by creating awareness among the professionals [12]. 
The various adverse effects caused by ACEIs include dry cough, 
angioedema, dizziness, hypotension, and hyperkalemia and those due 
to ARBs include angioedema, hypotension, and hypoglycemia [13]. 
The current study aims to analyze the prescription pattern, to identify 
the most common indications of ACEIs and ARBs, to identify the risk 
factors associated with cardiovascular diseases, and to evaluate the 
incidence of ACEIs and ARBs induced adverse effects in patients with 
cardiovascular diseases associated with the Department of Cardiology 
at a Charitable Tertiary Care Hospital.
METHODS
This was a prospective observational study conducted in a charitable 
tertiary care teaching hospital for a period of 6 months (October 
2016–March 2017). The study was approved by the institutional ethics 
committee (REF: INST. EC/EC/104/2016–2017). The subjects included 
both inpatients and outpatients of either gender with age 18 years and 
above, receiving ACEIs and/or ARBs at cardiology department.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Patients’ demographic details such as patients IP number, age, gender, 
date of admission, date of discharge, weight, height, BMI, complaints 
on admission, medical and medication history, alternative medications, 
diagnosis, risk factors, and the generic and brand names of the 
medications the patient is on, especially ACEIs and/or ARBs during 
the course of study were noted along with their indications, dose, 
frequency, and route of administration. Documentation form was 
prepared to record the ADRs related to ACEIs and ARBs. The recorded 
details were assessed using causality, Naranjo scale.
The data collected was compiled, tabulated in Microsoft Excel 2013. 
Quantitative variables were described as mean ± SD, and categorical 
variables were described as frequencies and percentages. Association 
of risk factors with cardiovascular diseases was tested using Chi-square 
test. p≤0.05 will be considered as statistical significance. Data were 
analyzed using Statistical Package for the Social Sciences version 16.0 
for windows.
RESULTS
Demographic status of study population
A total of 100 patients were included in this study. Of which 23 (23.0%) 
were female and 77 (77.0%) were male. In our study, male predominance 
was noted over female. The mean age of the study population was found 
to be 59.36±9.22 years. Among them, majority of the patients are under 
the age group of 41–60 (51%) years, and the other age distributions are 
provided in Fig. 1.
Incidence of risk factors
The most common risk factors associated with study population were 
found to be DM (39%) followed by smoking (20%), alcohol (14%), 
family history (6%), and obesity (4%) (Fig. 2).
Association of risk factors with cardiovascular diseases
Among the study population, the association between risk factors and 
cardiovascular disease were obtained by using Chi-square test. The 
results show some significant association between the cardiovascular 
diseases and risk factors as given in Table 1.
Indications of ACEIs and ARBs among the study population
The various indications of ACEIs and ARBs are shown in Table 2.The 
common indications of ACEIs were found to be IHD (17%) followed by 
HTN/IHD (12%), IHD/HF (12%), IHD/HF/HTN (9%), IHD/MR/HF/
HTN (5%), HF/HTN (4%), HTN (3%), HF/MR (2%), MR (2%), IHD/MR 
(1%), HTN/MR/IHD (1%), HF (1%), and AR (1%). The indications of 
ARBs were found as follows: HTN/IHD (16%), IHD/HTN/HF (4%), HTN 
(4%), IHD (3%), HTN/AR (2%), and IHD/MR/HF/HTN (1%).
Distribution patterns of ACEIs and ARBs in study population
The distribution patterns of ACEIs and ARBs indicate that majority 
of the study population were prescribed with ACEIs (70%) and ARBs 
(30%) (Fig. 3.1).
Among the 70 patients prescribed with ACEIs, the main two ACEIs 
prescribed including ramipril (69%) and enalapril (1%). Of 30 
prescribed with ARBs, the three different ARBs include telmisartan 
(18%), losartan (8%), and olmesartan (4%) (Fig. 3.2).
Incidence of ADRs related to ACEIs and ARBs
The main adverse effect was found as dry cough associated with ACEIs 
(5.71%). Causality assessment was done using Naranjo scale, and the 
assessment shows that the ADR was probable (Fig. 4).
DISCUSSION
In the current study, the results reveal that of 100 patients, the frequency 
of the use of ACEIs and ARBs was more in male patients (77.0%) than 
female patients (23.0%). Similar results were shown in accordance 
with the study conducted by Vakade et al. [14]. However, contradictory 
results were shown by the study conducted by Barrron et al. [15].
The present study, maximum numbers of patients were in the age group 
of 41–60 years. As far as age factor is concern, 3% patients belong to 
Table 1: Association between risk factors and cardiovascular disease.





1 Smoking HF 0.044
IHD+HTN+MR 0.044
2 DM IHD+HTN+HF 0.017
3 Obesity HTN+IHD 0.033
HF+HTN 0.029
4 Alcohol HF 0.013
AR 0.013
HF: Heart failure, IHD: Ischemic heart diseases, HTN: Hypertension, 
MR: Mitral regurgitation, AR: Aortic regurgitation
Table 2: Indication of ACEIS and ARBs
S. No Indications ACEIs (% of 
drug used)
ARBs (% of 
drug used)
1 HTN 3 4
2 IHD 17 3
3 HF 1 0
4 MR 2 0
5 AR 1 0
6 HTN+AR 0 2
7 IHD+MR 1 0
8 HF+MR 2 0
9 HTN+IHD 12 16
10 IHD+HF 12 0
11 HF+HTN 4 0
12 IHD+HTN+MR 1 0
13 IHD+HF+HTN 9 4
14 IHD+MR+HF+HTN 5 1
Total 70 30
ACEIS: Angiotensin-converting enzyme inhibitors, ARBs: Angiotensin receptor 
blockers, HTN: Hypertension, IHD: Ischemic heart diseases, HF: Heart failure, 
MR: Mitral regurgitation, AR: Aortic regurgitation
Fig. 1: Age-wise distribution
Fig. 2: Incidence of risk factors within the study population
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the age group of 20–40 years, 51% patients belong to the age group of 
41–60 years, and 46% are >60 years [7]. Similar results were shown by 
the studies conducted earlier [10,16,17].
The current study shows that the most common risk factors associated 
with study population were found to be DM (39%) followed by smoking 
(20%), alcohol (14%), family history (6%), and obesity (4%). Similar 
results were obtained from several studies which include a study 
conducted by Pereira et al. [18] shows that incidence of DM was less 
when compared to our study and obesity was found to be same and 
other studies by Baskota et al. [19] show that the incidence of alcohol 
intake was less and the incidence of smoking was more when compared 
to our study.
Of 100 patients studied, the most common indications of ACEIs were 
found to be IHD (17%) followed by HTN/IHD (12%), IHD/HF (12%), 
IHD/HF/HTN (9%), IHD/MR/HF/HTN (5%), HF/HTN (4%), HTN 
(3%), HF/MR (2%), MR (2%), IHD/MR (1%), HTN/MR/IHD (1%), HF 
(1%), and AR (1%), and the indications of ARBs were found as follows: 
HTN/IHD (16%), IHD/HTN/HF (4%), HTN (4%), IHD (3%), HTN/AR 
(2%), and IHD/MR/HF/HTN (1%). Similar results were obtained from 
the study conducted by Healey et al. shows that ACEIs and ARBs were 
indicated for AF, post-MI, HF, and HTN. In another study conducted by 
Deszi et al. [7] shows that ACEIs were used in the treatment of CHF, 
post-AMI, and CAD. ARBs are used only as a substituent if there is any 
ACEIs intolerance.
The result indicated that majority of the study population were 
prescribed with ACEIs (70%) and ARBs (30%). Among 70% of patients, 
mainly two ACEIs were prescribed, namely ramipril (69%) and 
enalapril (1%). The other 30% of patients were prescribed with ARBs, 
namely telmisartan (18%), losartan (8%), and olmesartan (4%). When 
comparing the result with other studies; the use of ACEIs was found to 
be more than that of ARBs in the present study [15,18]. A similar result 
was shown by Vakade et al. that ramipril was the most commonly used 
ACEIs [20]. Contrasting results were shown in other study conducted 
by Matteti et al. [6]. Among the ACEIs, perindopril was most commonly 
used followed by lisinopril and ramipril [21]. According to the study 
conducted by Vakade et al. [14], olmesartan was the commonly used 
ARBs.
While analyzing the patients who receive ACEIs and ARBs show dry 
cough (5.71%), as the main adverse effects associated with ACEIs. 
Similar results were found in a study conducted by Nazir et al. [22]. In 
another study conducted by Pereira et al. shows that the prevalence of 
cough was more in patients receiving ACEIs.
CONCLUSIONS
In this study, we identified that ACEIs and ARBs show clinical benefits 
when used in the treatment of various cardiovascular diseases such as 
IHD, HTN, HF, MR, and AR and we found that ACEIs are the commonly 
prescribed class of drugs than ARBs. ARBs were prescribed only in 
patients who do not tolerate ACEIs. Ramipril and telmisartan were 
the most commonly used ACEIs and ARBs, respectively, and the 
complications of cardiovascular diseases can be reduced by knowing 
the incidence of risk factors such as DM, smoking, family history, 
obesity, and alcohol intake.
Considering the other ADRs, cough is the most commonly occurred ADR 
with ACEIs, and an alternative therapy can be initiated by assessing 
the incidence of ADR related to ACEIs and ARBs. The overall study 
results help to determine the use of drug in the society and to avoid the 
inappropriate drug use.
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